Interplay between paclitaxel, gap junctions, and kinases: unraveling mechanisms of action and resistance in cancer therapy
Author:
- 29 March 2024
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-15
Abstract
Highlights Paclitaxel’s role in cancer therapy. Paclitaxel disrupts microtubule dynamics leading to cell cycle arrest and activation of various cell death pathways. Activation of gap junctions contributes to improved resistance against paclitaxel.Keywords
This publication has 100 references indexed in Scilit:
- Posttranslational Modifications in Connexins and PannexinsThe Journal of Membrane Biology, 2012
- Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcomeInternational Journal of Cancer, 2011
- Cytoplasmic accumulation of connexin32 protein enhances motility and metastatic ability of human hepatoma cells in vitro and in vivoInternational Journal of Cancer, 2007
- Connexin 32 potentiates vinblastine‐induced cytotoxicity in renal cell carcinoma cellsMolecular Carcinogenesis, 2006
- Paclitaxel and cyclosporine A show supra-additive antiproliferative effects on smooth muscle cells by activation of protein kinase C.Basic Research in Cardiology, 2002
- Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cellsInternational Journal of Cancer, 2001
- Protein Kinase C Isoform Expression and Activity Alter Paclitaxel Resistancein VitroGynecologic Oncology, 1999
- Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensationChromosoma, 1997
- Paclitaxel-induced apoptosis in HeLa cells is serum dependentJournal of Biochemical Toxicology, 1996
- Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMPMolecular Carcinogenesis, 1996